JERUSALEM, November 22, 2010 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that that the company's exhibition of its barcoded syringe locking device generated overwhelming interest at the annual Medica 2010 Conference in Dusseldorf Germany, held November 16-19.

A poll of companies that viewed Medisafe 1's demonstration, including manufactures and distributors of syringes and related technologies, revealed significant interest in the syringe, producing the locking device under license, or marketing the device.

The Medica Conference was the second such large medical conference that Medisafe 1 participated in during the month of November.

Medica is the world's largest annual exhibition in the medical sector, with over 135,000 participants and 4,000 exhibitors arriving from over 100 nations.

"The initial results of the Medica conference are overwhelmingly positive," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "The interest displayed in our technology has the potential to open up new business development channels in North America, Europe and Australia."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

    Contact:
    Jacob Elhadad
    CEO
    +972-524440000
    Jacob.elhadad10@gmail.com

SOURCE Medisafe 1 Technologies Corp.

Back to top